Back

HFpEF and HFrEF display different anabolic phenotypes as assessed by IGF-1 and IGFBP-1

21 May 2016 (17:12 - 17:30)
Organised by:
Congress Presentation Part of: Directions in HFpEF research HFpEF - Heart failure with preserved ejection fraction HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Doctor Ulrika Ljung Faxen

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
HfpEF 2020: opportunities to intervene
Professor R. De Boer (Rotterdam, NL)
Slides Video
Presentation thumbnail
Na+/Ca2+ Exchanger (NCX) inhibition with ORM 11035 improves cardiac function and remodeling without lowering blood pressure in a model of heart failure with preserved ejection fraction
Professor F. Heinzel (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
A restrictive pattern of LV filling is only present in one third of cardiac AL amyloidosis patients
Associate Professor S. Perlini (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Dipeptidyl peptidase 4 inhibitor sitagliptin reduces oxidative stress, endothelial dysfunction and preserves diastolic function in a rat model of heart failure with preserved ejection fraction
Doctor K. Urbanek (Naples, IT)
Abstract

Access the full session

Session thumbnail
Directions in HFpEF research

The Event

Event poster

HEART FAILURE 2016

21 May 2016 17:12 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources